Regen BioPharma, Inc. (RGBP)
USD 0.05
(-12.78%)
USD 0.05
(-12.78%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 176.56 Thousand USD | -4.83% |
| 2022 | 185.51 Thousand USD | 26.9% |
| 2021 | 146.19 Thousand USD | 32.9% |
| 2020 | 110 Thousand USD | 0.0% |
| 2019 | 110 Thousand USD | 10.0% |
| 2018 | 100 Thousand USD | -9.09% |
| 2017 | 110 Thousand USD | 10.0% |
| 2016 | 100 Thousand USD | -47.92% |
| 2015 | 192 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 44.06 Thousand USD | -0.68% |
| 2024 Q2 | 41.85 Thousand USD | -5.03% |
| 2024 Q3 | 36.56 Thousand USD | -12.63% |
| 2023 Q3 | 43.71 Thousand USD | -0.79% |
| 2023 Q1 | 44.06 Thousand USD | 80.85% |
| 2023 Q2 | 44.06 Thousand USD | 0.0% |
| 2023 FY | 176.56 Thousand USD | -4.83% |
| 2023 Q4 | 44.36 Thousand USD | 1.48% |
| 2022 Q3 | 58.71 Thousand USD | 35.39% |
| 2022 Q4 | 24.36 Thousand USD | -58.5% |
| 2022 FY | 185.51 Thousand USD | 26.9% |
| 2022 Q1 | 54.06 Thousand USD | 102.94% |
| 2022 Q2 | 43.37 Thousand USD | -19.78% |
| 2021 Q3 | 1.92 Million USD | 6910.01% |
| 2021 Q2 | 27.42 Thousand USD | -0.0% |
| 2021 FY | 146.19 Thousand USD | 32.9% |
| 2021 Q1 | 27.42 Thousand USD | -1.09% |
| 2021 Q4 | -1.84 Million USD | -195.77% |
| 2020 Q4 | 27.72 Thousand USD | 1.1% |
| 2020 FY | 110 Thousand USD | 0.0% |
| 2020 Q3 | 27.42 Thousand USD | 0.0% |
| 2020 Q2 | 27.42 Thousand USD | 0.0% |
| 2020 Q1 | 27.42 Thousand USD | -1.09% |
| 2019 Q3 | 27.42 Thousand USD | 0.0% |
| 2019 Q4 | 27.72 Thousand USD | 1.1% |
| 2019 FY | 110 Thousand USD | 10.0% |
| 2019 Q1 | 27.42 Thousand USD | 102.07% |
| 2019 Q2 | 27.42 Thousand USD | 0.0% |
| 2018 Q3 | 100 Thousand USD | 0.0% |
| 2018 Q4 | -1.32 Million USD | -1425.78% |
| 2018 FY | 100 Thousand USD | -9.09% |
| 2018 Q1 | - USD | 100.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 Q3 | 110 Thousand USD | 0.0% |
| 2017 Q4 | -2.4 Million USD | -2282.62% |
| 2017 FY | 110 Thousand USD | 10.0% |
| 2017 Q1 | - USD | -100.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 100.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | 100 Thousand USD | -47.92% |
| 2016 Q4 | 100 Thousand USD | 0.0% |
| 2015 Q2 | - USD | 100.0% |
| 2015 FY | 192 Thousand USD | 0.0% |
| 2015 Q1 | -5782.00 USD | 99.23% |
| 2015 Q4 | -1.83 Million USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | -754.86 Thousand USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 7339.032% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 98.492% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 155.26% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.852% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.684% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 465.859% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 242.099% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 98.823% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -5591.812% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 98.197% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -168.622% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 617.013% |
| Mesoblast Limited | -35.16 Million USD | 100.502% |
| Marizyme, Inc. | 457.7 Thousand USD | 61.425% |
| Genus plc | 178.7 Million USD | 99.901% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.92% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -183.74% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 56.954% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 1705.091% |
| ContraFect Corporation | -154 Thousand USD | 214.649% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 453.12% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -130.013% |
| IMV Inc. | -962.29 Thousand USD | 118.348% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 145.564% |
| MultiCell Technologies, Inc. | 49.32 USD | -357888.646% |
| ONE Bio Corp. | 20.12 Million USD | 99.123% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.562% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -261.063% |
| Q BioMed Inc. | -8988.00 USD | 2064.397% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.375% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 1244.71% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.602% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 115.466% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -152.229% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 3665.428% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -25.665% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 281.059% |
| GB Sciences, Inc. | -624.00 USD | 28394.872% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 305.236% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.998% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 84984.615% |
| Enzolytics Inc. | 30.7 Thousand USD | -474.964% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 63.402% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.984% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 134.316% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 71.402% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.957% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 2093.677% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 310.569% |
| Kadimastem Ltd | -630.13 Thousand USD | 128.019% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 82.129% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 98.163% |
| BioStem Technologies, Inc. | 15.42 Million USD | 98.855% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 1591.846% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 0.0% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 86.99% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 708.828% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 60.768% |
| SYBLEU INC | 11.69 Thousand USD | -1409.576% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 96.168% |
| Bioxytran, Inc. | -8285.00 USD | 2231.08% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 147.335% |
| Neutra Corp. | 14.33 Thousand USD | -1131.671% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 315.317% |
| PureTech Health plc | -1.6 Million USD | 111.014% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 117.634% |
| IXICO plc | 3.27 Million USD | 94.601% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 125.441% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 109.858% |
| CSL Limited | 7.7 Billion USD | 99.998% |
| Cellectis S.A. | 18 Thousand USD | -880.889% |